Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes.
Published May 1, 2014 · R. Henry, J. Rosenstock, Douglas K Logan
Journal of diabetes and its complications
76
Citations
1
Influential Citations
Abstract
Abstract removed due to Elsevier request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.
Study Snapshot
Key takeawayITCA 650 effectively maintains glycemic control and weight loss in metformin-treated type 2 diabetes patients for up to 48 weeks, with a lower incidence of adverse events compared to the initial 24-week treatment phase.
PopulationOlder adults (50-71 years)
Sample size24
MethodsObservational
OutcomesBody Mass Index projections
ResultsSocial networks mitigate obesity in older groups.